A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3)
Clinical Trial Grant
Awarded By
Pfizer, Inc.
Start Date
December 19, 2025
End Date
December 18, 2030
Awarded By
Pfizer, Inc.
Start Date
December 19, 2025
End Date
December 18, 2030